医学と薬学 78/6 2021年6月号

出版社: 自然科学社
発行日: 2021-05-27
分野: 薬学  >  雑誌
ISSN: 03893898
雑誌名:
特集: 肺がんに対する薬物治療
電子書籍版: 2021-05-27 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

2,200 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,760 円(税込)

目次

  • 特集 肺がんに対する薬物治療

    序文
    非小細胞肺がんに対する周術期治療の現状と展望
    切除不能局所進行非小細胞肺がんの治療
    ドライバー遺伝子変異を標的とした肺がん治療
    免疫チェックポイント阻害薬を用いた非小細胞肺がんの治療
    進展型小細胞肺がんの治療
    限局型小細胞肺がん治療の現状と今後の展望

    臨床試験
     新規がん疼痛治療薬ジクロフェナクナトリウム含有経皮吸収型製剤(HP-3150)の薬物動態

    Diagnosis
     全自動免疫測定装置HISCLにおける改良試薬の評価:FT4とCA19-9

    Health Care
     持続型抗菌成分Octadecyl dimethyl(3-triethoxysilylpropyl)ammonium chlorideの
      新型コロナウイルス(SARS-CoV-2)への抗ウイルス効果

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 肺がんに対する薬物治療】

P.699 掲載の参考文献
1) Arriagada R, Bergman B, Dunant A, et al : Cispla-tin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (4) : 351 -360, 2004.
2) Kato H, Ichinose Y, Ohta M, et al : A randomized trial of adjuvant chemotherapy with uracil-teg-afur for adenocarcinoma of the lung. N Engl J Med 350 (17) : 1713-1721, 2004.
3) NSCLC Meta-analysis Collaborative Group : Pre-operative chemotherapy for non-small-cell lung cancer : a systematic review and meta-analysis of individual participant data. Lancet 383 (9928) : 1561-1571, 2014.
4) Goss GD, O'Callaghan C, Lorimer I, et al : Gefitinib versus placebo in completely resected non-small-cell lung cancer : results of the NCIC CTG BR19 study. J Clin Oncol 31 (27) 3320-3326, 2013.
5) Kelly K, Altorki NK, Eberhardt WE, et al : Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT) : A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 33 (34) : 4007-4014, 2015.
6) Pennell NA, Neal JW, Chaft JE, et al : SELECT : A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol 37 (2) : 97 -104, 2019.
7) Zhong WZ, Wang Q, Mao WM, et al : Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104) : a randomised, open-label, phase 3 study. Lancet Oncol 19 (1) : 139-148, 2018.
8) Zhong WZ, Wang Q, Mao WM, et al : Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC : Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol 39 (7) : 713 -722 2021.
9) Wu YL, Tsuboi M, He J, et al : Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 383 (18) : 1711-1723, 2020.
10) Zhong WZ, Chen KN, Chen C, et al : Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103) : A Randomized Phase II Study. J Clin Oncol 37 (25) : 2235-2245, 2019.
11) 日本肺癌学会編 : 肺癌診療ガイドライン 2020年版, 金原出版. 東京, 2020.
12) Reck M, Rodriguez-Abreu D, Robinson AG, et al : Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 375 (19) : 1823-1833, 2016.
13) Antonia SJ, Villegas A, Daniel D, et al : Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 377 (20) : 1919-1929, 2017.
14) Antonia SJ, Villegas A, Daniel D, et al : Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 379 (24) : 2342-2350, 2018.
15) Hellmann MD, Chaft JE, William WN, et al : Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers : proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 15 (1) : e42-50, 2014.
16) Forde PM, Chaft JE, Smith KN, et al : Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 378 (21) : 1976-1986, 2018.
17) Provencio M, Nadal E, Insa A, et al : Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM) : an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21 (11) : 1413-1422, 2020.
18) Shu CA, Gainor JF, Awad MM, et al : Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer : an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21 (6) : 786-795, 2020.
19) Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 378 (2) : 158-168, 2018.
P.704 掲載の参考文献
1) Sause WT, Scott C, Taylor S, et al : Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588 : preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87 (3) : 198-205, 1995.
2) Yamamoto N, Nakagawa K, Nishimura Y, et al : Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer : West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28 (23) : 3739-3745, 2010.
3) Segawa Y, Kiura K, Takigawa N, et al : Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer : OLCSG 0007. J Clin Oncol 28 (20) : 3299-3306, 2010.
4) Scagliotti GV, Parikh P, von Pawel J, et al : Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 (21) : 3543-3551, 2008.
5) Senan S, Brade A, Wang LH, et al : PROCLAIM : Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 34 (9) : 953-962, 2016.
6) Ohyanagi F, Yamamoto N, Horiike A, et al : Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br J Cancer 101 (2) : 225-231, 2009.
7) Ichinose Y, Seto T, Sasaki T, et al : S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer : a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706). J Thorac Oncol 6 (12) : 2069-2075, 2011.
8) Kaira K, Tomizawa Y, Yoshino R, et al : Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Lung Cancer 82 (3) : 449-454, 2013.
9) Nogami N, Takigawa N, Hotta K, et al : A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer : the Okayama Lung Cancer Study Group Trial 0501. Lung Cancer 87 (2) : 141-147, 2015.
10) Taira T, Yoh K, Nagase S, et al : Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer. Cancer chemotherapy and pharmacology 81 (3) : 565-572, 2018.
11) Sasaki T, Seto T, Yamanaka T, et al : A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer : WJOG5008L. Br J Cancer 119 (6) : 675-682, 2018.
12) Niho S, Yoshida T, Akimoto T, et al : Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer : SPECTRA study. Lung Cancer 141 : 64-71, 2020.
13) Hanna N, Neubauer M, Yiannoutsos C, et al : Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer : the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26 (35) : 5755-5760, 2008.
14) Kelly K, Chansky K, Gaspar LE, et al : Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer : SWOG S0023. J Clin Oncol 26 (15) : 2450-2456, 2008.
15) Topalian SL, Hodi FS, Brahmer JR, et al : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (26) : 2443-2454, 2012.
16) Brahmer JR, Tykodi SS, Chow LQ, et al : Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (26) : 2455-2465, 2012.
17) Brahmer J, Reckamp KL, Baas P, et al : Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373 (2) : 123-135, 2015.
18) Borghaei H, Paz-Ares L, Horn L, et al : Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 373 (17) : 1627-1639, 2015.
19) Herbst RS, Baas P, Kim DW, et al : Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a randomised controlled trial. Lancet 387 (10027) : 1540-1550, 2016.
20) Rittmeyer A, Barlesi F, Waterkamp D, et al : Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK) : a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (10066) : 255-265, 2017.
21) Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al : Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 378 (22) : 2078-2092, 2018.
22) Paz-Ares L, Luft A, Vicente D, et al : Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 379 (21) : 2040-2051, 2018.
23) Socinski MA, Jotte RM, Cappuzzo F, et al : Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 378 (24) : 2288-2301, 2018.
24) West H, McCleod M, Hussein M, et al : Ate-zolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130) : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20 (7) : 924-937, 2019.
25) Antonia SJ, Villegas A, Daniel D, et al : Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 377 (20) : 1919-1929, 2017.
26) Antonia SJ, Villegas A, Daniel D, et al : Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 379 (24) : 2342-2350, 2018.
27) Furuse K, Fukuoka M, Kawahara M, et al : Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (9) : 2692-2699, 1999.
28) Curran WJ, Jr., Paulus R, Langer CJ, et al : Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer : randomized phase III trial RTOG 9410. J Natl Cancer Inst 103 (19) : 1452-1460, 2011.
29) Bradley JD, Paulus R, Komaki R, et al : Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617) : a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16 (2) : 187-199, 2015.
30) Bradley JD, Hu C, Komaki RR, et al : Long-Term Results of NRG Oncology RTOG 0617 : Standard-Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 38 (7) : 706-714, 2020.
P.714 掲載の参考文献
3) 日本肺癌学会 : 肺癌患者におけるEGFR遺伝子変異の手引き 第4.3版, 2020年3月31日.
4) Kobayashi S, Boggon TJ, Dayaram T, et al : EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352 : 786-792, 2005.
5) Pao W, Miller VA, Politi KA, et al : Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 : e73, 2005.
6) Mok TS, Wu YL, Ahn MJ, et al : Osimertinib or PlatinumPemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 376 : 629-640, 2017.
7) Soria JC, Ohe Y, Vansteenkiste J, et al : Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 378 : 113-125, 2018
8) Reungwetwattana T, Nakagawa K, Cho BC, et al : CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol : JCO2018783118, 2018.
9) 日本肺癌学会編 : 肺癌診療ガイドライン 2020年版. https://www.haigan.gr.jp/modules/guideline/index.php?content_id=3
10) Hosomi Y, Morita S, Sugawara S, et al : Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor : NEJ009 Study. J Clin Oncol 38 (2) : 115-123, 2020.
11) Seto T, Kato T, Nishio M, et al : Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) : an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 15 (11) : 1236-1244, 2014.
12) Yamamoto N, Seto T, Nishio M, et al : Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer (NSCLC) : Survival follow-up results of JO25567. J Clin Oncol 36 (suppl 15) : 9007, 2018.
13) Hosomi Y, Seto T, Nishio M, et al : Erlotinib plus bevacizumab (EB) versus Erlotinib alone (E) as first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation (mt) : JO25567 exploratory subgroup analysis. Ann Oncol 26 (Suppl 9) : 125, 2015.
14) Kazuhiko N, Edward B Garon, et al : Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20 (12) : 1655-1669, 2019.
15) Solomon BJ, Mok T, Kim DW, et al : First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371 (23) : 2167-217, 2014.
16) Wu YL, Lu S, Lu Y, et al : Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol 13 (10) : 1539 -1548, 2018.
17) Hida T, Nokihara H, Kondo M, et al : Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX) : an open-label, randomised phase 3 trial. Lancet 390 (10089) : 29-39, 2017.
18) Nakagawa K, Hida T, NokiharaH, et al : Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer, Lung Cancer 139 : 195-199, 2020.
19) Solomon BJ, Besse B, Bauer TM, et al : Lorlatinib in patients with ALK-positive non-small-cell lung cancer : results from a global phase 2 study. Lancet Oncol 19 (12) : 1654-1667, 2018.
20) Solomon B, Bauer TM, Marinis FD, et al : Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) : Results of the phase III CROWN study. Ann Oncol 31 (Suppl 4) : S1180-S1181, 2020.
21) Camidge DR, Kim HR, Ahn MJ, et al : Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 379 (21) : 2027-2039, 2018.
22) Lovly CM, Pao W : Escaping ALK inhibition : mechanisms of and strategies to overcome resistance. Sci Transl Med 4 (120) : 120ps2, 2012.
23) Katayama R, Friboulet L, Koike S, et al : Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 20 : 5686-5696, 2014.
24) Ignatius Ou SH, Azada M, Hsiang DJ, et al : Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802 RO5424802) in ALKrearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 9 : 549-553, 2014.
25) Friboulet L, Li N, Katayama R, et al : The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4 : 662-673, 2014.
26) Ou SH, Ahn JS, De Petris L, et al : Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer : a phase II global study. J Clin Oncol 34 (7) : 661-668, 2016.
27) Shaw AT, Gandhi L, Gadgeel S, et al : Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer : a single-group, multicentre, phase 2 trial. Lancet Oncol 17 (2) : 234 -242, 2016.
28) Kim DW, Tiseo M, Ahn MJ, et al : Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer : a randomized, multicenter phase II trial. J Clin Oncol 35 (22) : 2490-2498, 2017.
29) Crino L, Ahn MJ, De Marinis F, et al : Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib : results from ASCEND-2. J Clin Oncol 34 (24) : 2866-2873, 2016.
30) Nishio M, Yoshida T, Kumagai T, et al : Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors : Outcomes of the Phase 2 J-ALTA Trial. J Thorac Oncol 16 (3) : 452-463, 2021.
31) Bergethon K, Shaw AT, Ou SH, et al : ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30 : 863-870, 2012.
32) Shaw AT, Ou SH, Bang YJ, et al : Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371 (21) : 1963-1971, 2014
33) Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC) : updated results, including overall survival, from PROFILE 1001. Ann Oncol 30 (7) : 1121-1126, 2019.
34) Wu YL, Yang JC, Kim DW, et al : Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol 36 (14) : 1405-1411, 2018.
35) Sun Min Lim, Hye Ryun Kim, et al : Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol 35 (23) : 2613-2618, 2017.
36) Shaw AT, Solomon BJ, Chiari R, et al : Lorlatinib in advances ROS1-positive non-small-cell lung cancer : a multicentre, open-label, single-arm, phase1-2 trials. Lancet Oncol 20 (12) : 1691-1701, 2019.
37) Drilon A, Siena S, Dziadziuszko R, et al : Entrectinib in ROS1 fusion-positive non-small-cell lung cancer : integrated analysis of three phase 1-2 trials. Lancet Oncol 21 (2) : 261 -270, 2020.
38) 日本肺癌学会バイオマーカー委員会 : 肺癌患者における次世代シークエンサーを用いた遺伝子パネル検査の手引き, 2019年12月23日 第1.1版.
39) サーモフィッシャーサイエンティフィックジャパングループ, 2020年8月21日プレスリリース. https://www.thermofisher.com/jp/ja/home/about-us/news-gallery/release/2020/pr082120.html (2021年3月23日アクセス)
40) Paik PK, Arcila ME, Fara M, et al : Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29 : 2046-2051, 2011.
42) Planchard D, Smit EF, Groen HJM, et al : Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer : an open-label, phase 2 trial. Lancet Oncol 18 : 1307-1316, 2017.
43) Tong JH, Yeung SF, Chan AWH, et al : MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Clin Cancer Res 22 (12) : 3048-3056, 2016.
44) Paik PK, Felip E, Veillon R, et al : Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med 383 (10) : 931-943, 2020
45) Wolf J, Seto T, Han JY, et al : Capmatinib (INC280) in MET Δ ex14-mutated advanced non-small cell lung cancer (NSCLC) : Efficacy data from the phase II GEOMETRY mono-1 study. J Clin Oncol 37 (suppl 15) : 9004, 2019.
46) Yoh K, Seto T, Satouchi M, et al : Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET) : an open-label, multicentre phase 2 trial. Lancet Respir Med 5 (1) : 42-50, 2017.
47) Drilon A, Oxnard GR, Tan DSW, et al : Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 383 (9) : 813-824, 2020.
P.721 掲載の参考文献
2) Scagliotti GV, Parikh P, von Pawel J, et al : Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 (21) : 3543-3551, 2008.
3) Reck M, Rodriguez-Abreu D, Robinson AG, et al : Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 375 (19) : 1823-1833, 2016.
4) Cho BC, Wu Y, Lopes G, et al : FP13.04 KEYNOTE-042 3-Year Survival Update : 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC. J Thorac Oncol 16 (3 Suppl) : S225-S226, 2021.
5) Gadgeel S, Rodriguez-Abreu D, Speranza G, et al : Updated Analysis From KEYNOTE-189 : Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 38 (14) : 1505-1517, 2020.
6) Paz-Ares L, Vicente D, Tafreshi A, et al : A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC : Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol 15 (10) : 1657-1669, 2020.
7) Socinski MA, Jotte RM, Cappuzzo F, et al : Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 378 (24) : 2288-2301, 2018.
8) West H, McCleod M, Hussein M, et al : Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130) : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20 (7) : 924-937, 2019.
9) Papadimitrakopoulou V, Cobo M, Bordoni R, et al : IMpower132 : PFS and Safety Results with 1L Atezolizumab+Carboplatin/Cisplatin+Pemetrexed in Stage IV Non-Squamous NSCLC. J Thorac Oncol 13 (10 Suppl) : S332-S333, 2018.
10) Nishio M, Barlesi F, Ball S, et al : 375O-Final efficacy results from IMpower132 : First-line atezolizumab+chemotherapy in patients with stage IV non-squamous NSCLC. Ann Oncol 31 (suppl 6) : S1386-S1406, 2020.
11) Ramalingam SS, Ciuleanu TE, Pluzanski A, et al. Nivolumab+ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer : Three-year update from CheckMate 227 Part 1. J Clin Oncol 38 (15 suppl) : 9500, 2020.
12) Paz-Ares L, Ciuleanu TE, Cobo M, et al : First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA) : an international, randomised, open-label, phase 3 trial. Lancet Oncol 22 (2) : 198-211, 2021.
13) P Marino, A Preatoni, A Cantoni : Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 76 : 593-601, 1995.
14) Yamamoto N, Nakagawa K, Nishimura Y, et al : Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer : West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28 (23) : 3739-3745, 2010.
15) Curran WJ Jr, Paulus R, Langer C J, et al : Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer : Randomized Phase III Trial RTOG 9410. J Natl Cancer Inst 103 (19) : 1452 -1460, 2011.
16) Antonia SJ, Villegas A, Daniel D, et al : Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377 (20) : 1919-1929, 2017.
17) Antonia SJ, Villegas A, Daniel D, et al : Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379 (24) : 2342-2350, 2018.
18) Brahmer JR, Lacchetti C, Schneider BJ, et al : Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36 (17) : 1714-1768, 2018.
19) Gonzalez-Rodriguez E, Rodriguez-Abreu D : Immune Checkpoint Inhibitors : Review and Management of Endocrine Adverse Events. Oncologist 21 (7) : 804 -816, 2016.
20) Rizvi NA, Hellmann MD, Snyder A, et al : Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (6230) : 124-128, 2015.
21) Hellmann MD, Ciuleanu TE, Pluzanski A, et al : Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 378 (22) : 2093-2104, 2018.
22) Thommen DS, Koelzer VH, Herzig P, et al : A transcriptionally and functionally distinct PD-1 (+) CD8 (+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med 24 (7) : 994 -1004, 2018.
23) Kumagai S, Togashi Y, Kamada T, et al : The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 21 (11) : 1346-1358, 2020.
24) Qin S, Xu L, Yi M, et al : Novel immune check-point targets : moving beyond PD-1 and CTLA-4. Mol Cancer 18 (1) : 155, 2019.
25) Khan M, Arooj S, Wang H : NK Cell-Based Immune Checkpoint Inhibition. Front Immunol 11 : 167, 2020.
26) Yang Z, Guo J, Weng L, et al : Myeloid-derived suppressor cells-new and exciting players in lung cancer. J Hematol Oncol 13 (1) : 10, 2020.
27) Taylor MH, Lee CH, Makker V, et al : Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J Clin Oncol 38 (11) : 1154-1163, 2020.
28) Thomas A, Vilimas R, Trindade C, et al : Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC : Results from a Phase II Study. J Thorac Oncol 14 (8) : 1447 -1457, 2019.
29) Hellmann MD, Gettinger S, Chow LQM, et al : Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer. Int J Cancer 147 (7) : 1963-1969, 2020.
P.729 掲載の参考文献
2) Fukuoka M, Furuse K, Saijo N, et al : Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83 : 855-861, 1991
3) Okamoto H, Watanabe K, Kunikane H, et al : Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer : JCOG 9702. Br J Cancer 97 : 162-9, 2007
4) Horn L, Mansfield AS, Szczesna A, et al : First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 379 : 2220-2229, 2018
5) O'Brien ME, Ciuleanu TE, Tsekov H, et al : Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24 : 5441-5447, 2006
6) Goto K, Ohe Y, Shibata T, et al : Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605) : a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 17 : 1147-1157, 2016
7) Baize N, Monnet I, Greillier L, et al : Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer : an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 21 : 1224-1233, 2020
8) Horita N, Yamamoto M, Sato T, et al : Amrubicin for relapsed small-cell lung cancer : a systematic review and meta-analysis of 803 patients. Sci Rep 6 : 18999, 2016
P.736 掲載の参考文献
1) Hann CL, Wu MA, Rekhtman N et al : Ch. 49 Small Cell and Neuroendocrine Tumors of the Lung. DeVita, Hellman, & Rosenberg's Cancer, 11th ed. -Principles & Practice of Oncology (eds DeVita VT, Lawrence TS, Rosenberg SA), pp.671-700, Wolters Kluwer, 2019.
2) Hou JM, Krebs MG, Lancashire L, et al : Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 30 : 525-532, 2012.
3) Kalemkerian GP, Loo BW, Akerley W, et al : NCCN guidelines insights : small cell lung cancer, version 2. 2018. J. Natl Compr. Canc Netw 16 : 1171-1182, 2018.
4) Bray F, Ferlay J, Soerjomataram I, et al : Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68 : 394-424, 2018.
5) Forman D, Bray F, Brewster DH, et al : Cancer Incidence in Five Continents Volume X, International Agency for Research on Cancer, Lyon, 2014.
6) Francisci S, Minicozzi P, Pierannunzio D, et al : Survival patterns in lung and pleural cancer in Europe 1999-2007 : Results from the EUROCARE-5 study. Eur J Cancer 51 : 2242-2253, 2015.
7) Govindan R, Page N, Morgensztern D, et al : Changing epidemiology of small-cell lung cancer in the United States over the last 30 years : analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24 : 4539-4544, 2006.
8) Breitling LP, Rinke A, Gress TM : Recent survival trends in high-grade neuroendocrine neoplasms and lung cancer. Neuroendocrinology 110 : 225-233, 2020.
9) Huang R, Wei Y, Hung RJ, et al : Associated links among smoking, chronic obstructive pulmonary disease, and small cell lung cancer : a pooled analysis in the International Lung Cancer Consortium. EBioMedicine 2 : 1677-1685, 2015.
10) Varghese AM, Zakowski MF, Yu HA, et al : Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol 9 : 892-896, 2014.
11) Wang J, Liu Q, Yuan S, et al : Genetic predisposition to lung cancer : comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies. Sci Rep 7 : 8371, 2017.
12) Quintanal-Villalonga A, Chan JM, Yu HA, et al : Lineage plasticity in cancer : a shared pathway of therapeutic resistance. Nat Rev Clin Oncol 17 : 360-371, 2020.
13) Wang S, Tang J, Sun T, et al : Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Sci Rep 7 : 1339, 2017.
14) George J, Lim JS, Jang SJ, et al : Comprehensive genomic profiles of small cell lung cancer. Nature 524 : 47-53, 2015.
15) Davis S, Stanley KE, Yesner R, et al : Small-cell carcinoma of the lung-survival according to histologic subtype : a Veterans Administration Lung Group Study. Cancer 47 : 1863-1866, 1981.
16) Fruh M, De Ruysscher D, Popat S, et al : Small-cell lung cancer (SCLC) : ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24 : vi99-vi105, 2013.
17) Shepherd FA, Crowley J, Van Houtte P, et al : The International Association for the Study of Lung Cancer Lung Cancer Staging Project : proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2 : 1067-1077, 2007.
18) Vallieres E, Shepherd FA, Crowley J, et al : The IASLC Lung Cancer Staging Project : proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 4 : 1049-1059, 2009.
19) Nicholson AG, Chansky K, Crowley J et al : The International Association for the Study of Lung Cancer Lung Cancer Staging Project : proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 11 : 300-311, 2016.
20) Hochstenbag MM, Twijnstra A, Wilmink JT, et al : Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC) : MR-imaging is useful at initial diagnosis. J Neurooncol 48 : 243-248, 2000.
21) Rudin CM, Brambilla E, Faivre-Finn C, et al : Small-cell lung cancer. Nat Rev Dis Primers 7 : 3, 2021.
22) Karam I, Jiang SY, Khaira M, et al : Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide. Am J Clin Oncol 38 : 51-54, 2015.
23) Kubota K, Hida T, Ishikura S, et al : Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202) : a randomised phase 3 study. Lancet Oncol 15 : 106-113, 2014.
24) Antonia SJ, Villegas A, Daniel D, et al : Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379 : 2342-2350, 2018.
25) Horn L, Mansfield AS, Szczesna A, et al : First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379 : 2220-2229, 2018.
26) Paz-Ares L, Dvorkin M, Chen Y, et al : Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CAS-PIAN) : a randomised, controlled, open-label, phase 3 trial. Lancet 394 : 1929-1939, 2019.
27) Auperin A, Arriagada R, Pignon JP, e t al : Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group. N Eng. J Med 341 : 476-484, 1999.
28) Wakeam E, Acuna SA, Leighl NB, et al : Surgery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer : a propensity-matched analysis of survival. Lung Cancer 109 : 78-88, 2017.
29) Lad T, Piantadosi S, Thomas P, et al : A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 106 : 320S-323S, 1994.
30) Fox W, Scadding JG : Medical research council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet 2 : 63-65, 1973.
31) Barnes H, See K, Barnett S, et al : Surgery for limited-stage small-cell lung cancer. Cochrane Database Syst Rev 4 : CD011917, 2017.
32) Zhao H, Ren D, Liu H, et al : Comparison and discussion of the treatment guidelines for small cell lung cancer. Thorac Cancer 9 : 769-774, 2018.
33) Quoix E, Fraser R, Wolkove N, et al : Small cell lung cancer presenting as a solitary pulmonary nodule. Cancer 66 : 577-582, 1990.
34) Rami-Porta R, Wittekind C, Goldstraw P ; International Association for the Study of Lung Cancer (IASLC) Staging Committee : Complete resection in lung cancer surgery : proposed definition. Lung Cancer 49 : 25-33, 2005.
35) Yang CF, Chan DY, Speicher PJ, et al : Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer. J Clin Oncol 34 : 1057-1064, 2016.
36) Brock MV, Hooker CM, Syphard JE, et al : Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy : Its time has come. J Thorac Cardiovasc Surg 129 : 64-72, 2005.
37) Salem A, Mistry H, Hatton M, et al : Association of chemoradiotherapy with outcomes among patients with stage I to II vs stage III small cell lung cancer : secondary analysis of a randomized clinical trial. JAMA Oncol 5 : e185335, 2019.
38) Simone CB 2nd, Bogart JA, Cabrera AR, et al : Radiation therapy for small cell lung cancer : An ASTRO clinical practice guideline. Pract Radiat Oncol 10 : 158-173, 2020.
39) Verma V, Simone CB 2nd, Allen PK, et al : Multi-institutional experience of stereotactic ablative radiation therapy for stage I small cell lung cancer. Int J Radiat Oncol Biol Phys 97 : 362-371, 2017.
40) Wu AJ, Gillis A, Foster A, et al : Patterns of failure in limited-stage small cell lung cancer : Implications of TNM stage for prophylactic cranial irradiation. Radiother Oncol 125 : 130-135, 2017.
41) Yang Y, Zhang D, Zhou X, et al : Prophylactic cranial irradiation in resected small cell lung cancer : a systematic review with meta-analysis. J Cancer 9 : 433-439, 2018.
42) Zhu H, Guo H, Shi F, et al : Prophylactic cranial irradiation improved the overall survival of patients with surgically resected small cell lung cancer, but not for stage I disease. Lung Cancer 86 : 334-338, 2014.
43) Pignon JP, Arriagada R, Ihde DC, et al : A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327 : 1618-1624, 1992.
44) Faivre-Finn C, Snee M, Ashcroft L, et al : Concurrent once-daily versus twice-daily chemo-radiotherapy in patients with limited-stage small-cell lung cancer (CONVERT) : an open-label, phase 3, randomised, superiority trial. Lancet Oncol 18 : 1116-1125, 2017.
45) Turrisi AT 3rd, Kim K, Blum R, et al : Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 : 265-271, 1999.
46) Levy A, Hendriks LEL, Le Pechoux C, et al : Current management of limited-stage SCLC and CONVERT trial impact : Results of the EORTC Lung Cancer Group survey. Lung Cancer 136 : 145-147, 2019.
47) De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, et al : Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 17 : 543-552, 2006.
48) Fried DB, Morris DE, Poole C, et al : Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22 : 4837-4845, 2004.
49) Huncharek M, McGarry R : A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 9 : 665-672, 2004.
50) Pijls-Johannesma MC, De Ruysscher D, Lambin P, et al : Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 1 : CD004700, 2005.
51) Sun JM, Ahn YC, Choi EK, et al : Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol 24 : 2088-2092, 2013.
52) Christodoulou M, Blackhall F, Mistry H, et al : Compliance and outcome of elderly patients treated in the concurrent once-daily versus twicedaily radiotherapy (CONVERT) Trial. J Thorac Oncol 14 : 63-71, 2019.
53) Hu X, Bao Y, Xu YJ, et al : Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses. Cancer 126 : 840-849, 2020.
54) Le Pechoux C, Dunant A, Senan S, et al : Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01) : a randomised clinical trial. Lancet Oncol 10 : 467-474, 2009.
55) Takahashi T, Yamanaka T, Seto T, et al : Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 18 : 663-671, 2017.
56) Rusthoven CG, Kavanagh BD : Prophylactic cranial irradiation (PCI) versus active MRI surveillance for small cell lung cancer : the case for equipoise. J Thorac Oncol 12 : 1746-1754, 2017.
57) Sagman U, Lishner M, Maki E, et al : Second primary malignancies following diagnosis of small-cell lung cancer. J Clin Oncol 10 : 1525-1533, 1992.
58) Kono M, Allen PK, Lin SH, et al : Incidence of second malignancy after successful treatment of limited-stage small-cell lung cancer and its effects on survival. J Thorac Oncol 12 : 1696-1703, 2017.
59) Verma V, Fakhreddine MH, Haque W, et al : Cardiac mortality in limited-stage small cell lung cancer. Radiother Oncol 128 : 492-497, 2018.
60) Giuliani M, Sun A, Bezjak A, et al : Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma. Cancer 116 : 5694-5699, 2010.
61) Grosshans DR, Meyers CA, Allen PK, et al : Neurocognitive function in patients with small cell lung cancer : effect of prophylactic cranial irradiation. Cancer 112 : 589-595, 2008.
62) Peters S, Pujol J-L, Dafni U, et al : LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy : Results from the ETOP/IFCT 4-12 STIMULI trial. Annals of Oncol 31 (Suppl 4) : 1211, 2020.
63) Iams WT, Shiuan E, Meador CB, et al : Improved prognosis and increased tumor-infiltrating lymphocytes in patients who have SCLC with neurologic paraneoplastic syndromes. J Thorac Oncol 14 : 1970-1981, 2019.
64) Antonia SJ, Lopez-Martin JA, Bendell J, et al : Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032) : a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17 : 883-895, 2016.
65) Ready NE, Ott PA, Hellmann MD, et al : Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer : results from the checkmate 032 randomized cohort. J Thorac Oncol 15 : 426-435, 2020.
66) Chung HC, Piha-Paul SA, Lopez-Martin J, et al : Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC : results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol 15 : 618-627, 2020.
67) Doyle A, Martin WJ, Funa K, et al : Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med 161 : 1135-1151, 1985.
68) Yazawa T, Kamma H, Fujiwara M, et al : Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol 187 : 191-199, 1999.
69) Funa K, Gazdar AF, Minna JD, et al : Paucity of beta 2-microglobulin expression on small cell lung cancer, bronchial carcinoids and certain other neuroendocrine tumors. Lab Invest 55 : 186-193, 1986.
70) Traversari C, Meazza R, Coppolecchia M, et al : IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Ther 4 : 1029-1035, 1997.
71) Wang W, Hodkinson P, McLaren F, et al : Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate. Int J Cancer 131 : E928-E937, 2012.
72) Eerola AK, Soini Y, Paakko P : A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 6 : 1875-1881, 2000.
73) Makarenkova VP, Shurin GV, Tourkova IL, et al : Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells. J Neuroimmunol 145 : 55-67, 2003.
74) Higgins KA, Gorgens S, Sudmeier LJ, et al : Recent developments in limited stage small cell lung cancer. Transl Lung Cancer Res 8 : S147-S152, 2019.
75) Gronberg BH, Killingberg KT, Flotten O, et al : High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer : an open-label, randomised, phase 2 trial. Lancet Oncol 22 : 321-331, 2021.

【臨床試験】

P.757 掲載の参考文献
1) World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents, pp. 25-29, 2018.
2) 特定非営利活動法人 日本緩和医療学会 ガイドライン統括委員会編, がん疼痛の薬物療法に関するガイドライン 2020年版. 第3版, pp.97-106, 金原出版株式会社, 東京, 2020.
3) 特定非営利活動法人 日本緩和医療学会 ガイドライン統括委員会編, がん疼痛の薬物療法に関するガイドライン 2020年版. 第3版, pp.39-42, 金原出版, 東京, 2020.
4) 葛谷雅文 : 嚥下困難. 日老医誌 47 : 390-392, 2010.
5) 井上莊一郎, 竹内護 : NSAIDs経静脈製剤の使用法と注意点. Mod Physician 32 : 1378-1381, 2012.
6) 水島裕, 丁宗鉄, 矢船明史, 他 : 健常人におけるジクロフェナクナトリウム坐剤 (ボルタレンサポ) および錠剤 (ボルタレン錠) 単回投与後の忍容性と生物学的利用性. 炎症 8 : 475-482, 1988.
7) ノバルティスファーマ株式会社 : ボルタレン錠25mg添付文書. 第16版, 2016.
8) 角尾道夫, 吉村敬治, 丸山洋子, 他 : 徐放性ジクロフェナクナトリウムカプセル (SR-318) の単回投与ならびに連続投与におけるジクロフェナクおよび代謝物の体内動態. Prog Med 9 : 877-892, 1989.
9) 久光製薬社内資料.

【Diagnosis】

P.765 掲載の参考文献
1) 細羽恵美子, 高柳嘉代, 三浦ひとみ, 他 : 免疫発光測定装置ルミパルスLS2400による「ルミパルスプレストCA19-9」改良試薬の性能評価. 医学と薬学 76 (5) : 735-743, 2019.
2) 諏訪有香, 齋藤翠, 藤田孝, 他 : 生化学汎用自動分析装置における高感度CRPの性能評価. 医学と薬学 75 (3) : 245-251, 2018.
3) 北川亘, 宮崎直子, 田中克昌, 他 : エクルーシス試薬FT4 IIIを用いた基礎的・臨床的検討. 医学と薬学 75 (6) : 681-692, 2018.
4) 高柳嘉代, 細羽恵美子, 三浦ひとみ, 他 : 免疫発光測定装置ルミパルスLS2400による「ルミパルスプレストCEA」改良試薬の性能評価. 医学と薬学 76 (5) : 745-753, 2019.
5) 出口松夫, 鎌田正智, 吉岡範, 他 : 抗HBs抗体国際標準品 (WHO 2nd) を基準としたHBs抗体測定試薬「アーキテクト オーサブ・アボット」の評価. 医学と薬学 74 (9) : 1137-1144, 2017.
6) Nafija S : The Comparison Between Different Immunoassays for Serum Carbohydrate Antigen (CA19-9) Concentration Measurement. Acta Inform Med 26 (4) : 235-239, 2018.
7) 佐々木健太, 佐野剛史, 伊藤万里子, 他 : 血清CA19-9の測定値方法間差と分子多様性に関する検討 第一報 : 腫瘍性疾患と脾腫陽性疾患における血清CA19-9のArchitectとLumipulse による免疫反応性の差異. 臨床化学 46 : 311-317, 2017.
8) 渡邊剛, 竹下享典, 室谷孝志, 他 : CA19-9の機種間による測定値差の検討と考察. 医学と薬学 77 (6) : 945-952, 2020.
9) 畑中徳子, 伊東裕之, 佐藤京子, 他 : CA19-9測定試薬の違いによるデータ乖離. JJCLA 32 (5) : 825-828, 2007.
10) Kristina H, Pi : Comparison of three immuno-assays for CA19-9. Clinica Chimica Acta 400 : 123-127, 2009.
11) 菊池良介, 度會理佳, 鈴木敦夫, 他 : 5種類のcarbohydrate antigen 19-9 試薬測定による相関及び膵臓がん診断能評価. 医学検査 69 (2) : 184-192, 2020.
12) Rita P, Maria C, Sara B, et al : The Pitfalls of CA19-9. Am J Clin Pathol 138 : 281-287, 2012.
13) Sonia L, William R, et al : Performance Characteristics of Five Automated CA19-9 Assays. Am J Clin Pathol 127 : 436-440, 2007.
14) 種本和雄, 小長英二, 竹内仁司, 他 : Carbohydrate Antigen 19-9 (CA19-9) 測定値の検討. 日臨外会誌 48 (1) : 30-37, 1987.
15) 小口寿夫, 本間達二, 長田敦夫, 他 : モノクローナル抗体にて認識される新しい腫瘍マーカー, CA19-9の臨床的意義の検討. 日消誌 81 (6) : 1430-1435, 1984.
16) 吉村龍太, 芳賀克夫, 江上寛, 他 : 腫瘍マーカーCA19-9およびCA125の消化器疾患における臨床的意義 : 特に膵癌, 胆道癌診断の有用性について. 日消外会誌 18 (7) : 1687-1692, 1985.
17) 外山久太郎, 安達献, 三富弘之, 他 : 良性疾患における血清CA19-9高値例の検討. 北里医学 15 : 259-264, 1985.
18) 横山俊伸, 池堂ゆかり, 木戸文子, 他 : 非腫瘍性良性呼吸器疾患におけるシアリル糖鎖抗原の検討. 日呼吸会誌 36 (10) : 851-856, 1998.
19) 矢島義昭, 後藤和弘, 町田優, 他 : 任意型健診におけるCA19-9測定の意義について. 人間ドック 29 : 610-615, 2014.
20) 鈴木朋子, 今井瑞香, 窪田素子, 他 : 人間ドック受診者における腫瘍マーカーCA19-9高値例の検討. 人間ドック 30 : 22-29, 2015.
21) 吉村裕, 吉原愛, 渡邊奈津子, 他 : 甲状腺関連ホルモン検査試薬の基準値に関する検討. 医学と薬学 76 (5) : 713-723, 2019.
22) 内田恵理香, 鈴木尚子, 高橋美佐, 他 : cobas, ARCHITECT, CentaurによるTSH, FT4, FT3測定値の比較検討. 医学と薬学 74 (8) : 923-931, 2017
23) 吉永英世, 櫻井昇, 塩澤瞭一 : 健康診断における甲状腺疾患のスクリーニング. 日本人間ドック学会誌 7 : 47-49, 1992.
24) 末廣史恵 : 検診における甲状腺疾患の発見率. 日本人間ドック学会誌 12 (2) : 38-41, 1997.
25) 香宗我部滋, 村上博男, 日ヶ久保利明, 他 : 総合検診における甲状腺疾患の有病率, 発見率について. 日健診誌 14 (3) : 401-406, 1987.
26) 金子陽介, 中島篤子, 中原フミ子 : 健診データ10年間から見た潜在性甲状腺機能異常症の疫学. 総合健診 44 (3) : 485-491, 2017.
27) Linda G, Katleen U, Dries R, et al : Standardization of Free Thyroxine Measurements Allows the Adoption of a More Uniform Reference Interval. Clinical Chemistry 63 (10) : 1642-1652, 2017.
28) 菱沼昭 : 甲状腺ホルモン測定の国際標準化とハーモナイゼーション. 臨床病理 65 (5) : 579-583, 2017.
29) 阿部好文, 網野信行, 飯高誠, 他 : 日本甲状腺学会編, バセドウ病治療ガイドライン 2011, pp.41-50, 南光堂, 東京, 2011.
30) 荒田尚子, 磯崎収, 今泉美彩, 他 : 日本甲状腺学会編, バセドウ病治療ガイドライン 2019, pp.45-46, 南光堂, 東京, 2019.

【Health Care】

P.775 掲載の参考文献
1) 千酌浩樹 : 新型コロナウィルス感染症. 鳥取医誌 48 (1, 2) : 4-11, 2020.
2) WHO (World Health Organization) HP https://www.who.int/emergencies/diseases/novel-coronavirus-2019 〔2021年3月9日閲覧〕
3) 山田英子 : 災害看護に必要な感染対策. 看護教育 55 (5) : 440-444, 2014.
4) 厚生労働省HP https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/syoudoku_00001.html 〔2021年3月9日閲覧〕
5) Neeltje van Doremalen, Trenton Bushmaker, Dylan H Morris, et al : Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. N Engl J Med 17 : NEJMc2004973, 2020.
6) 二川浩樹, 柚下香織, 平松美菜子, 他 : インフルエンザの拡大リスクを軽減する化合物. ケミカルエンジニアリング 55 (8) : 41-47, 2010.
7) 木全基樹, 泉澤勝弘, 二川浩樹. 持続型抗菌成分エトキシシラン系消毒薬 (Etak(R)) を主成分とした抗菌剤使用によるウィルス感染予防効果. 医学と薬学 76 (9) : 1331-1341, 2019.
8) 経済産業省HP https://www.meti.go.jp/press/2020/05/20200529005/20200529005.html 〔2021年3月9日閲覧〕
9) Ko K, Nagashima S, Bunthen E, et al : Molecular Characterization and the mutation pattern of SARS-CoV-2 during first and second wave outbreaks in Hiroshima, Japan. PLOS ONE 16 (2) : e0246383, 2021. (doi : 10.1371/journal.pone.0246383)
10) 増田道明 : 新型コロナウイルスのウイルス学的特徴. モダンメディア 66 (11) : 313-320, 2020.
11) Martina Bianchi, Domenico Benvenuto, Marta Giovanetti, et al : Sars-CoV-2 Envelope and Membrane Proteins : Structural Differences Linked to Virus Characteristics? Biomed Res Int 30 : 4389089, 2020.
12) 横畑綾治, 石田悠記, 西尾正也, 他 : 接触感染経路のリスク制御に向けた新型ウイルス除染機序の科学的基盤~コロナウイルス, インフルエンザウイルスを不活性化する化学物質群のシステマティックレビュー~. リスク学研究 30 (1) : 1-24 : 2020.
13) 高麗寛紀 : ジェミニ型第四アンモニウム塩の分子設計と抗菌活性. オレオサイエンス 6 (5) : 247-255, 2006.
14) Max Bueckert, Rishi Gupta, Aditi Gupta, et al : Infectivity of SARS-CoV-2 and Other Coronaviruses on Dry Surfaces : Potential for Indirect Transmission. Materials (Basel). 13 (22) : 5211, 2020.
15) Fernstrom A, Goldblatt M : Aerobiology and Its Role in the Transmission of Infectious Diseases. J Pathog 2013 : 1-13, 2013.
16) Boone SA, Gerba CP : Significance of Fomites in the Spread of Respiratory and Enteric Viral Disease. Appl Environ Microbiol 73 : 1687-1696, 2007.
17) FE Buckland, DA Tyrrell : Loss of infectivity on drying various viruses. Nature 195 : 1063-1064, 1962.
18) Myndi G. Holbrokk, et al : "Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1." The NEW ENGLAND JOURNAL of MEDICINE. DOI : 10.1056/NEJMc2004973, April, 8, 2020.
19) H Fathizadeh, P Maroufi, M Momen-Heravi, et al. Protection and disinfection policies against SARSCoV-2 (COVID-19). Infez Med 28 (2) : 185-191, 2020.

最近チェックした商品履歴

Loading...